JPH04152861A - Nutrient composition for nutrition - Google Patents

Abstract

PURPOSE:To obtain the subject composition having excellent pharmaceutical activity and useful for patient, etc., by using a specific fat, protein, etc., or amino acid, carbohydrate, mineral and vitamin as main components. CONSTITUTION:The objective composition is composed mainly of (A) a fat having a fatty acid composition containing 0-60% medium-chain fatty acid (e.g. caprylic acid), 3-20% (omega 3-type fatty acid (e.g. alpha-linolenic acid) and 10-40% omega6-type fatty acid (e.g. linolic acid) wherein the ratio of (omega 3-type fatty acid)/(omega 6-type fatty acid) is >=1/6 (preferably 2/1 to 1/5), (B) a protein composed of a milk protein and soybean protein at a (milk protein)/(soybean protein) ratio of 1/3 to 3/1 or decomposition product of the protein or an amino acid such as methionine and (C) carbohydrate (e.g. glucose), minerals (e.g. Na) and vitamins.

Description

[Detailed Description of the Invention] The present invention provides a nutritional composition with pharmaceutical activity that can be used to supply nutritional support to subjects who require nutritional support before and after surgical operations, or during medical diseases. relating to things.

Limb 11° C. 1 amount Various nutritional compositions have been used in the surgical and medical fields in the past. This nutritional composition contains many nutritional components such as lipids and proteins.

Among these, lipids are composed of medium-chain fatty acid triglycerides, which are extremely rapidly digested and absorbed, and soybean oil, corn oil, safflower oil, etc., which have a high content of linoleic acid. The essential fatty acids in lipids are mainly linoleic acid, and like linoleic acid, α-
Riluic acid is present in very small amounts. Neurological symptoms such as paresthesia and dermatitis have been reported as α-liluinate deficiency in humans.Furthermore, in recent years, the physiological functions of ω3 series (α-lyluinate) fatty acids and their metabolites have been elucidated, and ω- The importance of the role of α-lyluic acid, which is a starting material for 3-series metabolism, has been recognized. That is, α-lylunic acid and its metabolites eicosapencitric acid and docosahexaenoic acid show improvement in serum lipids, antithrombotic effect, anti-inflammatory effect, antihypertensive effect, immunosuppressive effect, tendency to suppress tumor metastasis, etc. Expectations are high for its effectiveness in preventing and improving various diseases.

As mentioned above, currently commercially available nutritional compositions have a low content of α-lyluic acid and are designed with emphasis placed only on linoleic acid, so it is difficult to recognize that they are balanced compositions. With the advancement of tube feeding methods, it has become possible to use nutritional compositions from the early stages of surgery, and with the spread of home tube feedings, the period of use of tube feedings has become longer. A nutritional composition with a well-balanced /ω6 fatty acid ratio is desired.

Proteins such as milk protein, soybean protein, and egg protein are used in consideration of amino acid composition, protein zero value, absorbability, etc. Alternatively, their decomposition products or amino acids or combinations thereof have also been used. It has been reported that nitrogen sources derived from soybean protein, its decomposition products, or a combination of soybean protein and milk protein have an effect on improving serum lipids, lowering blood pressure, etc. In addition, it is well known that serum lipids are improved by polyunsaturated fatty acids such as linoleic acid, α-lylunic acid, eicosapentaenoic acid, and docosahexaenoic acid, and by the combination of various nitrogen sources such as protein with lipids. There are high expectations for nutritional compositions having pharmacological activity.

On the other hand, the most frequent side effect of oral and tube feeding is diarrhea, especially in cases where it is administered after surgery.
Diarrhea has become a major problem plaguing patients and health care workers in general. From this, it is no exaggeration to say that the goal of developing oral and tube feeding compositions has always been to prevent the occurrence of diarrhea.

If diarrhea occurs during nutritional administration, measures are taken to slow down the injection rate of the nutritional composition, and in the worst case, administration must be discontinued. In this case, since the necessary and sufficient amount of heat cannot be given to the patient, parenteral nutritional support, which is considered unphysiological, has to be performed. Therefore, the development of a nutritional composition that suppresses the occurrence of diarrhea is an issue that must be solved as soon as possible.

The inventors of the present invention have carried out intensive studies on nutritional compositions that have a low incidence of diarrhea and have pharmaceutical activity. Using a fat containing ω3 fatty acids such as citric acid and docosahexaenoic acid, and ωθ fatty acids such as linoleic acid, the ratio was set to ω3 fatty acid/ω6 fatty acid 176
Based on the above, we found that it has many medicinal activities such as suppressing the decrease in the ratio of ω3 fatty acids/ω6 fatty acids in serum fatty acids and preventing the occurrence of diarrhea. and soybean protein in a specific ratio, i.e. milk protein/soybean protein 173-3/1
The present invention was made based on these findings.

That is, an object of the present invention is to provide an oral tube feeding composition having pharmaceutical activity that can be used in the surgical field, internal medicine field, and the like.

The nutritional composition according to the present invention is characterized by a combination of specific lipids and proteins in a certain ratio.

That is, the lipids include 0 to 60% medium chain fatty acids, 3 to 20% ω3 fatty acids, and 10 to 40% ω6 fatty acids, and the ratio of ω3 fatty acids to ωθ fatty acids is ω3 fatty acids/ω6 fatty acids 176%. A lipid having the above fatty acid composition is used. Further, as the protein, a protein is used which is composed of milk protein and soybean protein, and the ratio of the two is 173 to 3/1 (milk protein/soybean protein).

For lipids, we use medium-chain fatty acid triglyceride, which is digested and absorbed extremely quickly, and preferably medium-chain triglyceride, which is suitable for patients who have undergone gastrointestinal surgery, especially patients who have undergone gastrointestinal surgery, whose digestive absorption is significantly reduced. 0 to 60% by weight, more preferably 20 to 60% by weight. In addition, the fatty acid composition contains ω3 fatty acids, particularly preferably 3 to 20% α-liluic acid, and ω6 fatty acids, particularly preferably linoleic acid, in an amount of 10 to 40% by weight, and the ratio of ω3 fatty acids/ω6 fatty acids. is 1/6 or more, preferably 27
1 to 115. The ω3 fatty acid is selected from α-linolenic acid, eicosanpentaenoic acid, and docosahexaenoic acid, and the ω6 fatty acid is linoleic acid. In the present invention, animal and vegetable oils and fats containing these fatty acids are used. Examples of oils containing ω3 fatty acids and ω6 fatty acids include edible oils such as perilla oil, perilla oil, linseed oil, tung oil, fish oil, safflower oil, corn oil, soybean oil, and rapeseed oil.

Furthermore, in order to obtain a desired ω3 fatty acid/ω6 fatty acid ratio, a combination of two or more of these may be used.

Proteins (nitrogen sources) include milk protein, soybean protein, rabbit protein, etc. and their decomposition products, as well as neutral, acidic, and basic amino acids such as aliphatic amino acids, oxyamino acids, sulfur-containing amino acids, and aromatic amino acids. I can give an example. Preferably,
Using high-quality milk protein and soy protein that are easily digested and absorbed, it prevents diarrhea, improves reliability, has pharmacological activity,
From the viewpoint of cardiovascular diseases and chronic diseases, the mixing ratio of milk protein and soy protein should be 1:3 to 3:1.

In addition, examples of IN substances constituting the composition of the present invention include dextrin, sucrose, glucose, galactose, maltose, etc. in order not to increase osmotic pressure etc.
Other minerals include Na, KCa, Mg, P,
C1, Fe, Zn, Cu, Mn, etc., and vitamins such as fat-soluble vitamins such as A, D, E, and K, B, B2. B,, B, □, C1 Water-soluble vitamins such as pantothenic acid, niacin, biotin, and folic acid can be exemplified.

The nutritional composition of the present invention is in powder or liquid form, and can be administered orally or by tube depending on the situation.

EXAMPLES The present invention will be explained in more detail by showing Examples and Test Examples below.

(Example) Example 1 A liquid composition having the following composition was prepared.

Ingredient composition g/100m acid casein 3.85 isolated soy protein
1.29 dextrin
16.16 Soybean oil 0.82
Perilla oil 0.16 Medium chain fatty acid triglycerides (MCT) 1.02 High purity soybean phospholipids 0.16 Mifucyls
0.60 vitamins
0.06 purified water 82.6 g
The fatty acid composition of this lipid is 42.5% caprylic acid, α-
Consisting of 7.6% linolenic acid and 25.8% linoleic acid,
The ratio of ω3 fatty acids/ω6 fatty acids was 0.29.

In addition, the ratio of acid casein to isolated soy protein is 3.0.
Met.

Example 2 A powder composition having the following composition was prepared.

Ingredient composition Weight % Acid casein 5.39 Isolated soy protein 16.17 Methionine
0.31 dextrin
66.14 Soybean oil 2.43
Fish oil'a condensate 2.53 Palm oil
2.88 High purity soybean phospholipid
1.03 Minerals 3
．． 00 Vitamins 0.12 The fatty acid composition of this lipid was 65% caprylic acid, 3.2% α-linolenic acid, and 25.7% linoleic acid, and the content of ω3 fatty acids/ω6 fatty acids was 0.6. . In addition, acid casein/isolated soybean protein was 0.33.

(Test Example) Next, the effect of the nutritional composition of the present invention will be explained using a test example.

A small intestine resection model was created in which male Wistar rats (weighing about 200 g) were fasted overnight, and the abdomen was opened under general anesthesia to remove about 60% of the small intestine. For this rat,
The test nutritional composition was tested at a concentration of IKca 12 /lat of 13
The effect was tested by oral administration for 1 day.

Table 1 shows the composition of the composition used in the test at 100Kcal 7100d. The nutritional composition (A) is the composition of Example 1 of the present invention, and the ω3 fatty acid/ω6 fatty acid ratio is 10/33.95. The nutritional composition (B) is
A commercially available nutritional supplement whose lipids are composed of medium-chain fatty acid triglycerides and soybean oil, whose ratio of ω3 fatty acids/ω6 fatty acids is 0.14, and whose nitrogen sources are milk protein, whey protein, and soybean protein. be. The nutritional composition (C) is a commercially available nutritional supplement whose lipid is composed only of corn oil, the ratio of ω3 fatty acids/ω6 fatty acids is 0.04, and the nitrogen source is casein and soybean protein. The number of rats administered with each test nutrient was 8 each.

The results of the above tests are shown in FIGS. 1 to 3.

Figure 1 shows ω3 fatty acids (α-liluic acid, eicosapentaenoic acid, and docosahexaenoic acid) and ω6 fatty acids (
linoleic acid and arachidonic acid). Compared to other commercially available nutritional compositions (B) and (C), the nutritional composition (A) of the present invention has a higher concentration of ω3 fatty acids/ω6
The fatty acid ratio was high. This indicates that the nutritional composition (A) of the present invention has an effect of suppressing a decrease in the ratio of ω3 fatty acids/ω6 fatty acids in serum fat.

FIG. 2 shows serum albumin levels, which are generally used as an indicator of nutritional status.

The value was higher when the nutritional composition (A) of the present invention was administered than when the other nutritional compositions (B) and (C) were administered. This indicates that it has the highest nutritional value.

Figure 3 shows serum total cholesterol.

It is said that an increase in serum cholesterol is one of the factors that cause circulatory system diseases such as arteriosclerosis, and this time, the administration of the nutritional composition (C) significantly increased the cholesterol level. On the other hand, with the nutritional composition (A) of the present invention, no increase was observed, the physiological range was maintained, and the effect of suppressing the increase was observed.

Table 2 and FIG. 4 show the cumulative values of reliability characteristics for each day when each test nutritional composition was administered. It was shown that the nutritional composition (A) of the present invention suppressed the occurrence of diarrhea throughout the administration period and had good stool quality compared to other nutritional supplements (B) and (C).

Table 2 Reliability during administration of each test nutritional composition Total number of occurrences (times) during the administration period As recognized from the results of the above-mentioned animal test, the nutritional composition of the present invention was administered to patients, typically post-surgical patients. The administration of this drug prevents a decrease in the ratio of ω3 fatty acids to ω6 fatty acids in serum, and also suppresses the occurrence of diarrhea, which is difficult for medical professionals to treat, and maintains a good nutritional status. .

It was confirmed that the nutritional composition of Example (2) also had similar pharmacological activity.

[Brief explanation of the drawing]

Figure 1 shows the ratio of ω3 fatty acids/ω6 fatty acids in serum fatty acids when the nutritional compositions of the present invention (A) and comparative examples (B) and (C) were administered. Albumin values and Figure 3 show serum cholesterol levels. FIG. 4 shows the cumulative pattern of reliability statements for each day of administration of each nutritional composition. In the figure, ** indicates p<0.01, and p<0.05. Composition Composition Composition (^) (B) (C) **: p<001 * p<0.05 Figure 1 Composition Composition Composition (A) (B) (C) *: p<0 .05 (A) ('B) (C)**: Significant difference p<0.01

Claims (5)

[Claims] (1) The fatty acid composition contains 0 to 60% medium chain fatty acids, 3 to 20% ω3 fatty acids, and 10 to 40% ω6 fatty acids, and the ratio of ω3 fatty acids/ω6 fatty acids is 1/6 or more. A nutritional composition for nutritional supplementation whose main ingredients are certain lipids, proteins or their decomposition products, amino acids, carbohydrates, minerals, and vitamins. (2) Protein consists of milk protein and soy protein, and the ratio of both is milk protein/soy protein 1/3 to 3/
1. The nutritional composition for nutritional supplementation according to claim (1). (3) The medium chain fatty acid is caprylic acid, the ω3 fatty acid is at least one fatty acid selected from the group consisting of α-linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid, and the ω6 fatty acid is linoleic acid. Claim (1
) or the nutritional composition for nutritional supplementation according to (2). (4) The nutritional composition for nutritional supplementation according to any one of claims (1) to (3), wherein the ω3 fatty acid is α-linolenic acid and the ω6 fatty acid is linoleic acid. (5) Claim (1) wherein the ratio of ω3 fatty acids to ω6 fatty acids is 2/1 to 1/5.
The nutritional composition for nutritional supplementation according to any one of (4) to (4).